The role of klotho in systemic sclerosis

Prior research has shown that klotho is a hormone linked to aging and fibrotic processes. However, no prior work had resolved its role in systemic sclerosis (SSc). Established knowledge includes klotho's involvement in regulating oxidative stress and fibrosis in tissues like the kidney and skin. That uncertainty drove this investigation into SSc, a complex autoimmune disorder with fibrotic manifestations. It was already known that SSc patients exhibit progressive fibrosis in the skin and internal organs. This gap motivated the study to measure klotho levels in SSc patients and compare them to healthy controls. No prior work had resolved whether klotho levels correlate with disease severity or subtype in SSc. The researchers propose that klotho may serve as a biomarker for fibrotic processes in this condition. However, the study's limitations remain unclear at this stage.

The aim was to evaluate klotho's role in systemic sclerosis (SSc) pathogenesis by comparing its serum concentration in patients versus healthy controls. The specific problem addressed is the lack of understanding about klotho's involvement in SSc and its potential as a biomarker. The motivation stems from klotho's known role in fibrosis and aging. The researchers propose that measuring klotho could help identify disease mechanisms or subtypes in SSc. The study sought to determine if klotho levels correlate with clinical features like skin thickening or lung involvement. No prior work had resolved whether klotho levels differ in SSc patients versus controls. The researchers propose that lower klotho levels may reflect systemic fibrotic processes. However, the study's limitations remain unclear at this stage.

The study used ELISA assays to measure serum klotho levels in blood samples from 69 SSc patients and 77 healthy controls. SSc patients were evaluated for disease activity using the modified Rodnan's Skin Score and Medsger's scale. Pulmonary function tests and 2D-echocardiography were used to assess visceral involvement. Nailfold capillaroscopy and laboratory tests provided additional clinical data. Patients were categorized by disease subtype, including diffuse SSc. Controls were age- and sex-matched to the patient group. The study included patients receiving IV prostanoids and various immunosuppressive drugs. Statistical analysis compared klotho levels between groups using the Mann-Whitney U test and Spearman's correlation.

The median serum klotho concentration was significantly lower in SSc patients (0.23 ng/mL) compared to healthy controls (0.60 ng/mL; p<0.001). However, no significant correlation was found between klotho levels and disease activity markers. The study included 19 patients with diffuse SSc (27.5% of the cohort). Patients were on IV prostanoids and various immunosuppressive therapies. Klotho levels did not correlate with modified Rodnan's Skin Score or Medsger's scale. No association was found between klotho and pulmonary function test results. Similarly, no correlation was observed with echocardiographic findings or nailfold capillaroscopy. The lack of association suggests klotho may not serve as a marker for disease severity in SSc.

The authors propose that SSc patients have significantly lower serum klotho levels compared to healthy controls. However, no significant association was detected between klotho levels and clinical or laboratory features of the disease. The researchers suggest that klotho may not serve as a biomarker for disease severity in SSc. The study's limitations include a relatively small sample size and lack of longitudinal follow-up. The authors propose that further investigations are needed to clarify klotho's role in SSc pathogenesis. No prior work had resolved whether klotho levels correlate with SSc subtypes or treatment responses. The researchers suggest that klotho's role in SSc remains unclear and requires additional studies. The authors propose that future research should explore klotho's function in fibrotic processes specific to SSc.